Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monalizumab + trastuzumab
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Monalizumab + trastuzumab is an investigational combination therapy consisting of two monoclonal antibodies. Monalizumab is a first-in-class humanized IgG4 monoclonal antibody that targets the inhibitory immune checkpoint receptor NKG2A, expressed on natural killer (NK) cells and some CD8+ T cells, thereby unleashing their anti-tumor activity. Trastuzumab is a humanized IgG1 monoclonal antibody targeting the HER2/neu (ERBB2) receptor, commonly overexpressed in certain cancers such as HER2-positive breast cancer; it mediates its effect through inhibition of HER2 signaling and by promoting antibody-dependent cell-mediated cytotoxicity (ADCC). The rationale for combining these agents is to enhance immune-mediated tumor cell killing by both blocking inhibitory signals on effector lymphocytes (via monalizumab) and targeting tumor cells for destruction via ADCC (via trastuzumab). This combination has been studied in metastatic HER2-positive breast cancer patients who have progressed after prior anti-HER2 therapies[1][2][4][10].
- Other names
- monalizumab + trastuzumab
02
Targets
KLRD1 (CD94/NKG2A complex)ERBB2 (Erb-b2 receptor tyrosine kinase 2)KLRC1 (Killer cell lectin-like receptor subfamily C member 1)
Beyond the preview
Go deeper on monalizumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monalizumab + trastuzumab.